← Human Trials & Peer-Reviewed Studies
Antiendometrial antibodies in endometriosis measured by an enzyme-linked immunosorbent assay before and after treatment with danazol and nafarelin
Plain-language guide to PMID 2140439 (1990): double-blind randomized controlled trial study of Nafarelin in 35 women, endometriosis.
Key Facts
- PMID
- 2140439
- Journal
- Obstetrics and gynecology
- Year
- 1990
- Study type
- Randomized Controlled Trial
- Authors
- Kennedy SH et al. (5 authors)
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Nafarelin in the context of endometriosis.
No previous study has investigated prospectively the quantitative effect of treatment on antiendometrial antibody levels in endometriosis.
Who Took Part
According to the abstract, 35 women were involved.
By PubMed's age tags, the people studied were adults, women only.
The researchers measured antiendometrial antibody levels by an enzyme-linked immunosorbent assay in 35 women with laparoscopically proved endometriosis who were treated for 6 months with danazol (N = 11) or nafarelin (N = 24) in a randomized double-blind study.
How the Study Was Run
The design is described as randomized, double-blind and multicenter.
The women were allocated by chance, so the Nafarelin group and the comparison group should start out alike.
As a double-blind Nafarelin study, the assignments were hidden from both participants and investigators until the end.
Running at several centres spread the Nafarelin study over different clinics and patient groups.
The methods mention a period of 6 months.
What Was Measured
No previous study has investigated prospectively the quantitative effect of treatment on antiendometrial antibody levels in endometriosis.
The subject headings attached to it are Autoantibodies, Danazol, Endometriosis, Endometrium, Enzyme-Linked Immunosorbent Assay, Gonadotropin-Releasing Hormone and Nafarelin.
What This Means in Plain Language
The paper is a randomized, double-blind and multicenter study of Nafarelin in 35 women in people with endometriosis over 6 months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1990 (Obstetrics and gynecology), a journal based in United States.
More context: the Nafarelin compound page, Endometriosis research.
Our Notes on the Compound
Nafarelin: A GnRH analog nasal spray (Synarel) used in endometriosis and early puberty.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.